Not a good buy right now for an impatient investor: the trend is clearly bearish (SMA_200 > SMA_20 > SMA_5) and near-term pattern probabilities point to further downside (next day/week/month all negative).
Even though RSI is getting closer to oversold (RSI_6 ~32), there is no proprietary buy signal today to justify stepping in early.
Best call based on the provided data: avoid/new money should stay out; if already holding, this setup favors reducing/exiting into any bounce rather than buying.
Momentum: MACD histogram is negative (-0.0129) and still below zero (bearish), though “negatively contracting” hints downside momentum may be easing rather than reversing.
RSI: RSI_6 at ~32 is near oversold (not a confirmed reversal signal by itself).
Key levels: Pivot 6.037 (price below pivot = bearish). Immediate support S1 5.739 then S2 5.555; resistance R1 6.335 then R2 6.519.
Price context: Closed at 5.8 (down -1.85% regular session), still weak vs key pivot/resistances.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning (open interest): Put/Call OI ratio at 0.08 is extremely call-heavy (bullish leaning), but it can also reflect speculative calls rather than informed conviction.
Activity (volume): Today’s options volume is 0 (no meaningful real-time sentiment from volume).
Volatility: IV 30d ~106.66 vs historical vol ~50.22 implies options are priced for very large moves (uncertainty/earnings risk premium).
IV regime: IV percentile ~65.74 (elevated vs its own history), reinforcing “event/uncertainty” pricing.
Technical Summary
Sell
9
Buy
4
Positive Catalysts
scheduled for 2026-02-24 pre-market could act as a catalyst if results/guidance surprise positively.
Neutral/Negative Catalysts
Pattern-based forecast: 90% probability suggests continued weakness (-0.96% next day, -1.29% next week, -4.57% next month).
No analyst rating or price target change data was provided in the dataset, so a trend assessment of Wall Street upgrades/downgrades cannot be made here.
With the available information only, the “pros vs cons” view skews negative near-term: modest revenue growth is outweighed by worsening losses and margin compression, plus a bearish technical setup.
Wall Street analysts forecast INGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INGN is 13 USD with a low forecast of 12 USD and a high forecast of 14 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast INGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INGN is 13 USD with a low forecast of 12 USD and a high forecast of 14 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.660
Low
12
Averages
13
High
14
Current: 5.660
Low
12
Averages
13
High
14
B. Riley
NULL -> Buy
initiated
$14
AI Analysis
2025-06-17
Reason
B. Riley
Price Target
$14
AI Analysis
2025-06-17
initiated
NULL -> Buy
Reason
B. Riley initiated coverage of Inogen with a Buy rating and $14 price target.
B. Riley
Anderson Schock
Buy
initiated
$14
2025-06-17
Reason
B. Riley
Anderson Schock
Price Target
$14
2025-06-17
initiated
Buy
Reason
B. Riley analyst Anderson Schock last night initiated coverage of Inogen with a Buy rating and $14 price target. Inogen is a global leader in portable oxygen therapy, targeting chronic obstructive pulmonary disease patients, the analyst tells investors in a research note. The firm says the company's portable oxygen concentrators convert ambient air into medical-grade oxygen, allowing for greater patient mobility than traditional oxygen tanks. It believes Inogen represents a "compelling turnaround story" following a management transition in Q4 of 2023 focused on reducing friction among sales channels and on cost management strategies to drive sustainable and profitable growth. Riley views Inogen "deeply undervalued" and is encouraged by the company's turnaround momentum and five consecutive quarters of beating the Street's estimates.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for INGN
